Please login to the form below

Not currently logged in
Email:
Password:

Keppra

This page shows the latest Keppra news and features for those working in and with pharma, biotech and healthcare.

UCB bags FDA approval for epilepsy drug Briviact

UCB bags FDA approval for epilepsy drug Briviact

Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets. ... Briviact is positioned as a successor to Keppra, which despite

Latest news

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Interview with Roch Doliveux, UCB Interview with Roch Doliveux, UCB

    Though Keppra is now off patent in the US and going off patent in the EU in 2011, it will still be a significant product for many years to come because ... Our largest patent expiries – the trigger to make big changes - were going to occur (and did

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics